Phase 3 trial of INOpulse finishes dosing; top-line data expected soon
Dosing is complete in the Phase 3 REBUILD clinical trial testing INOpulse (inhaled nitric oxide) in people with pulmonary fibrosis at risk of developing pulmonary hypertension. In the blinded part of the study, which is now complete, participants were randomly assigned to receive nitric oxide or a placebo administered…